Skip to main content

Table 5 Toxicities associated with treatment

From: Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study

toxicities CCRT(N = 55) chemotherapy(N = 86)  
Gr.1 Gr.2 Gr.3 Gr.4 ≥Gr. 3 Gr.1 Gr.2 Gr.3 Gr.4 ≥Gr. 3 P
Leucocytopenia 11 (20.0%) 17 (30.9%) 19 (34.5%) 4 (7.3%) 41.8% 19 (22.1%) 43 (50.0%) 16 (18.6%) 5 (5.8%) 24.4% 0.040
Thrombocytopaenia 27 (49.1%) 12 (21.8%) 6 (10.9%) 0 (0.0%) 10.9% 45 (52.3%) 24 (27.9%) 7 (8.1%) 1 (1.2%) 9.3% 0.779
Anemia 37 (67.3%) 9 (16.4%) 1 (1.8%) 0 (0.0%) 1.8% 52 (60.5%) 15 (17.4%) 1 (1.2%) 0 (0.0%) 1.2% 0.647
Nausea/vomiting 28 (50.9%) 16 (29.1%) 2 (3.6%) 0 (0.0%) 3.6% 47 (54.7%) 16 (18.6%) 6 (7.0%) 0 (0.0%) 7.0% 0.483
liver injury 6 (10.9%) 1 (1.8%) 0 (0.0%) 0 (0.0%) 0% 10 (11.6%) 2 (2.3%) 0 (0.0%) 0 (0.0%) 0%
treatment-related pneumonitis 19 (34.5%) 7 (12.7%) 4 (7.3%) 0 (0.0%) 7.3%  
treatment-related esophagitis 24 (43.6%) 16 (29.1%) 8 (14.5%) 0 (0.0%) 14.5%  
  1. Abbreviations: CCRT concurrent chemoradiotherapy, Gr grade